Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.joms.2004.10.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Meta-regression of optic nerve imaging and visual outcome in myelin oligodendrocyte glycoprotein antibody optic neuritis.
J Neurol Sci
January 2025
Toronto Eye Specialists and Surgeons, Toronto, Ontario, Canada; Department of Ophthalmology & Vision Science, University of Toronto, Toronto, Ontario, Canada; Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Neurology, Department of Medicine, University of Toronto, Canada. Electronic address:
Background: Few predictors of visual outcome after myelin oligodendrocyte glycoprotein (MOG) auto-antibody disease optic neuritis (ON) have been reliably elucidated. We evaluate whether between-study differences in ON neuroimaging regional enhancement features may underlie heterogeneity in reported visual prognosis.
Methods: PROSPERO (CRD42024580123).
Imaging Yield, Surgical Findings, and Outcomes Following Surgical Excision of Lateral Brow Dermoid Cysts.
J Craniofac Surg
December 2024
Department of Surgery, Division of Plastic, Mayo Clinic.
Purpose: To review cases of lateral brow dermoid cysts and gain insight into the utility of preoperative imaging, incidence of intraorbital extension, and recurrence rate.
Methods: This is a retrospective study of all patients who underwent excision of lateral brow dermoid cysts at the authors' academic center over a 37-year period.
Results: A total of 136 patients were included.
[Clinical and imaging characteristics and influencing factors of myelin oligodendrocyte glycoprotein antibody-associated disease with different IgG antibody conversions].
Zhonghua Yi Xue Za Zhi
December 2024
Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing100730, China.
To investigate the clinical and imaging characteristics of patients with myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated disease (MOGAD) with different MOG-IgG seroconversions, and to analyze the factors affecting the conversion. Retrospective study. Patients diagnosed with MOGAD in the Department of Neurology, Beijing Tongren Hospital, Capital Medical University from January 2019 to April 2023 were included and the follow-up ended in May 2024.
View Article and Find Full Text PDFOrbital Inflammatory Manifestations in a Patient With VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) Syndrome.
J Neuroophthalmol
November 2024
Department of Neuro-Ophthalmology (BDC, RGF, SS, NS, SR), Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia; Department of Neurology (EDS, SR), Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Radiology (HAP), University of Michigan, Ann Arbor, Michigan; Department of Haematology (PP), Royal Melbourne Hospital, Melbourne, Victoria, Australia; and Department of Neurology (PR, NS), St Vincent's Hospital, Melbourne, Victoria, Australia.
An 84-year-old man with a genetically confirmed diagnosis of VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome treated with tocilizumab reported with a 3-day history of left eye pain, conjunctival chemosis and injection, and horizontal binocular diplopia. Examination revealed restriction of left eye ductions in all directions with mild unilateral proptosis. MRI of his brain and orbits demonstrated abnormal enhancement of the left posterior sclera and intraorbital optic nerve sheath, without involvement of the extraocular muscles, cavernous sinus, or optic nerve parenchyma.
View Article and Find Full Text PDFMOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally.
Autoimmun Rev
January 2025
Translational Neuroimmunology Group, Faculty of Medicine and Health, University of Sydney, Kids Neuroscience Centre, Children's Hospital at Westmead, Sydney, Australia; Sydney Medical School and Brain and Mind Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Department of Neurology, Concord Hospital, Sydney, Australia. Electronic address:
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is one of the most common antibody-mediated CNS disorders. Optimal diagnostic and prognostic biomarkers remain unclear. Our aim was to clarify these biomarkers and therapeutic outcomes internationally.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!